dzcon

Have you noticed any change in how tech journalists and investors treat new startup founders - even those with impressive connections and supporters - after the Theranos ordeal? Many in academia and biotech were highly skeptical of their blood tests long before the extent of the fraud was known, because the company hadn't even published a shred of data demonstrating efficacy while claiming to have leaped ahead of far more experienced scientists and microfluidics researchers with their tech. It was exasperating that so few journalists took the doubts seriously or even cared to look for them in the midst of hype about Elizabeth Holmes.